Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Sumitomo Dainippon Sues 2 Gx Makers over Latuda, Delays New 5-Year-Plan Announcement
Sumitomo Dainippon Pharma has filed patent infringement lawsuits in the US over the use patent of its bread-and-butter antipsychotic Latuda (lurasidone), prompting the company to shelve the announcement of its new five-year business plan scheduled for March to an unspecified…
To read the full story
Related Article
- Sumitomo Dainippon Settles Latuda Patent Lawsuits in US, New 5-Year Biz Plan Due Out Next Spring
November 28, 2018
- Sumitomo Dainippon Operating Profit Plummets 50% on Drug Price Cut, Generic Erosions
October 31, 2018
- Latuda Use Patent Suit Could Wrap Up in December: Sumitomo Dainippon Chief
May 14, 2018
- US Appeals Court Favors Sumitomo Dainippon in Latuda Substance Patent Suit
April 19, 2018
- Sumitomo Dainippon Sues 15 More Companies over Latuda Patent
February 27, 2018
BUSINESS
- Keytruda Holds Top Spot for 35th Straight Month in August: Encise
September 7, 2026
- Fuji Curbs Shipments of Simponi, Ranmark Biosimilars Soon after Launch
September 4, 2026
- Leqembi Subcutaneous Autoinjector Approved in China
September 4, 2026
- Nxera Gets US$8.6 Million OX2R Milestone from Centessa
September 4, 2026
- Top Medipal Shareholder Seeks CEO Ouster, Special Dividend
September 4, 2026
Japan has entered a third straight year of wage hikes averaging 5%, but the pharmaceutical industry is struggling to keep…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…